P.0353 Study protocol: psilocybin as a treatment for anorexia nervosa: a pilot study

On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.

“…The indications range across an entire spectrum of MDD/TRD, PTSD, GAD, bipolar disorders, pain, substance use and eating disorders, late-stage cancer-related anxiety and depression, autism spectrum disorders and the list keeps increasing. There are multiple generally small scale clinical trials in healthy volunteers or in various indications with psychedelics either as mostly psychological support-assisted monotherapies (Kaelen et al, 2015;Carhart-Harris et al, 2015;2018;Erritzoe et al, 2018;Stroud et al, 2018;Agin-Liebes et al, 2020;Hutten et al, 2020;Mertens et al, 2020;Pokorny et al, 2020;Madsen et al, 2020;Uthaug et al, 2020;Davis et al, 2020;Preller et al, 2020;Spriggs et al, 2020;Verrous et al, 2021;Kaertner et al, 2021;Douglass et al, 2022;Bosch et al, 2022;Duerler et al, 2020;Holze et al, 2021;Family et al, 2020;Müller et al, 2022;Sondergaard et al, 2022;Rucker et al, 2022;Jensen et al, 2022;Burmester et al, 2023;Allen et al, 2024;Eckernas et al, 2023;Good et al, 2023;Ledwos et al, 2023;Mason et al, 2023;Vogt et al, 2023;von Rotz et al, 2023) or as combinations with other psychedelics/entactogens (de Win et al, 2006;Carhart-Harris et al, 2014;Vizeli et al, 2022;Borissova et al, 2024;Heresco-Levy and Lerer, 2023;…”